Empiric versus pre-emptive antifungal strategy in high-risk neutropenic patients on fluconazole prophylaxis: a randomized trial of the European organization for Research and Treatment of cancer (EORTC 65091).
Johan MaertensTom LodewyckJ Peter DonnellySylvain ChantepieChristine RobinNicole BlijlevensPascal TurlureDominik SelleslagFrédéric BaronMickael AounWerner J HeinzHartmut BertzZdeněk RáčilBernard VandercamLubos DrgonaValerie CoiteuxCristina Castilla LlorenteCornelia Schaefer-ProkopMarianne PaesmansLieveke AmeyeLiv MeertKin Jip CheungDeborah A HeplerJürgen LoefflerRosemary BarnesOscar MarchettiPaul E VerweijFrederic LamothPierre Yves BochudMichael SchwarzingerCatherine Cordonniernull nullnull nullPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)
The pre-emptive antifungal strategy was safe for high-risk neutropenic patients given fluconazole as prophylaxis, halving the number of patients receiving antifungals without excess mortality or IFDs.